Bioterrorism

References

The author has no commercial relationships with manufacturers of products or providers of services discussed in this subsection.

1. Davis CJ: Nuclear blindness: an overview of the biological weapons programs of the former Soviet Union and Iraq. Emerg Infect Dis 5:509, 1999 [PMID 10458954]

2. Stern J: The prospect of domestic bioterrorism. Emerg Infect Dis 5:517, 1999 [PMID 10458956]

3. Kortepeter MG, Parker GW: Potential biological weapons threats. Emerg Infect Dis 5:523, 1999

4. Alibek K: Biohazard. Random House, Inc. New York, 1999

5. Henderson DA: The looming threat of bioterrorism. Science 283:1279, 1999 [PMID 10037590]

6. Biological and chemical terrorism: strategic plan for preparedness and response. Recommendations of the CDC Strategic Planning Workgroup. MMWR Morb Mortal Wkly Rep 49:1, 2000

7. Gerberding JL, Hughes JM, Koplan JP: Bioterrorism preparedness and response: clinicians and public health agencies as essential partners. JAMA 287:898, 2002 [PMID 11851584]

8. Lane HC, Fauci AS: Bioterrorism on the home front: a new challenge for American medicine. JAMA 286:2595, 2001 [PMID 11722275]

9. Meningococcal disease and college students. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 49:13, 2000

10. Bell BP, Goldoft M, Griffin PM, et al: A multistate outbreak of Escherichia coli 0157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers: the Washington experience. JAMA 272:1349, 1994 [PMID 7933395]

11. Weber DJ, Rutala WA: Pertussis: a continuing hazard for healthcare facilities. Infect Control Hosp Epidemiol 22:736, 2001 [PMID 11876450]

12. Measles, mumps, and rubella: vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 47:1, 1998

13. Prevention of varicella. Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 48:1, 1999

14. Bolyard EA, Tablan OC, Williams WW, et al: Guideline for infection control in healthcare personnel, 1998. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 19:386, 1998

15. Suspected brucellosis case prompts investigation of possible bioterrorism-related activity-New Hampshire and Massachusetts, 1999. MMWR Morb Mortal Wkly Rep 49:509, 2000

16. Duchin JS, Koster FT, Peters CJ, et al: Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The Hantavirus Study Group. N Engl J Med 330:949, 1994

17. Fine A, Layton M: Lessons from the West Nile viral encephalitis outbreak in New York City, 1999: implications for bioterrorism preparedness. Clin Infect Dis 32:277, 2001 [PMID 11170918]

18. Pandemic influenza: confronting a re-emergent threat. Proceedings of a meeting. Bethesda, Maryland, 11-13 December 1995. J Infect Dis 176:S1, 1997

19. Update: investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR Morb Mortal Wkly Rep 50:941, 2001

20. Control of Communicable Diseases Manual, 17th ed. Chin JE, Ed. American Public Health Association, Washington DC, 2000

21. Garner JS: Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol 17:53, 1996 [PMID 8789689]

22. Immunization of health-care workers. Recommendations of the Advisory Committee on Immunization Practices and the Hospital Infection Control Practices Advisory Committee. MMWR Morb Mortal Wkly Rep 46:1, 1997

23. Rotz LD, Khan AS, Lillibridge SR, et al: Public health assessment of potential bioterrorism agents. Emerg Infect Dis 8:225, 2002 [PMID 11897082]

24. Torok TJ, Tauxe RV, Wise RP, et al: A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars. JAMA 278:389, 1997 [PMID 9244330]

25. Kolavic SA, Kimura A, Simons SL, et al: An outbreak of Shigella dysenteriae type 2 among laboratory workers due to intentional food contamination.

26. Pavlin JA: Epidemiology of bioterrorism. Emerg Infect Dis 5:528, 1999 [PMID 10458958]

27. Recognition of illness associated with the intentional release of a biologic agent. MMWR Morb Mortal Wkly Rep 50:893, 2001

28. Vaccinia (smallpox) vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Morb Mortal Wkly Rep 50:1, 2001

29. Franz DR, Jahrling PB, Friedlander AM, et al: Clinical recognition and management of patients exposed to biological warfare agents. JAMA 278:399, 1997 [PMID 9244332]

30. Draft Supplemental Recommendation of the ACIP. Use of Smallpox (Vaccinia) Vaccine, June 2002. http://www.cdc.gov/nip/smallpox/supp_recs.htm

31. Fenner F, Henderson DA, Arita I, et al: Smallpox and its eradication. World Health Organization, Geneva.

http://www.who.int/emc/diseases/smallpox/Smallpoxeradication.html

32. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281:2127, 1999

33. Breman, JG, Henderson DA: Diagnosis and management of smallpox. N Engl J Med 346:1300, 2002 [PMID 11923491]

34. Henderson DA: Smallpox: clinical and epidemiologic features. Emerging Infect Dis 5:537, 1999 [PMID 10458961]

35. CDC Interim smallpox response plan and guidelines.

http://www.bt.cdc.gov/agent/smallpox/response-plan/index.asp

36. Lane JM, Ruben FL, Neff JM, et al: Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 122:303, 1970 [PMID 4396189]

37. Acha PN, Szyfres B: Zoonoses and Communicable Disease Common to Man and Animals, 3rd ed. Vol I. Pan American Health Organization, Washington, DC, 2001

38. Swartz MN: Recognition and management of anthrax: an update. N Engl J Med 345:1621, 2001 [PMID 11704686]

39. Brachman PS: Bioterrorism: an update with a focus on anthrax. Am J Epidemiol 155:981, 2002 [PMID 12034576]

40. Update: investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis. MMWR Morb Mortal Wkly Rep 50:973, 2001

41. Cieslak TJ, Eitzen HM Jr: Bioterrorism: agents of concern. J Public Health Manag Pract 6:19, 2000 [PMID 10977609]

42. Kournikakis B, Armour SJ, Boulet CA, et al: Risk assessment of anthrax threat letters. Technical Report 2001-048. Defense Research Establishment, Suffield, Canada, 2001

43. Dixon TC, Meselson M, Guillemin J, et al: Anthrax. N Engl J Med 341:815, 1999 [PMID 10477781]

44. Sirisanthana T, Brown AE: Anthrax of the gastrointestinal tract. Emerg Infect Dis 8:649, 2002 [PMID 12095428]

45. Inglesby TV, O'Toole T, Henderson DA, et al: Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236, 2002 [PMID 11980524]

46. Meselson M, Guillemin J, Hugh-Jones M, et al: The Sverdlovsk anthrax outbreak of 1979. Science 266:1202, 1994 [PMID 7973702]

47. LaForce FM. Anthrax. Clin Infect Dis 19:1009, 1994

48. Jernigan JA, Stephens DS, Ashford DA, et al: Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 7:933, 2001

49. Brachman PS: Inhalation anthrax. Ann NY Acad Sci 353:83, 1980 [PMID 7013615]

50. USAMRIID's Medical Management of Biological Casualties Handbook (USAMRIID Blue Book), 4th ed. United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, February, 2001

http://www.usamriid.army.mil/education/bluebook.html

51. Use of anthrax vaccine in the United States. Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 49:1, 2000

52. Considerations for distinguishing influenza-like illness from inhalational anthrax. MMWR Morb Mortal Wkly Rep 50:984, 2001

53. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep 50:909, 2001

54. Update: investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR Morb Mortal Wkly Rep 50:889, 2001

55. Statement by the Department of Health and Human Services regarding additional options for preventive treatment for those exposed to inhalational anthrax. Dec. 18, 2001.

http://www.hhs.gov/news/press/2001pres/20011218.html

56. Committee to Assess the Safety and Efficacy of the Anthrax Vaccine. Medical Follow-Up Agency: The Anthrax Vaccine: Is It Safe? Does It Work? Joellenbeck LM, Zwanziger LL, Durch JS, et al, Eds: Institute of Medicine, National Academy Press, Washington, DC, 2002

http://www.iom.edu/iom/iomhome.nsf/Wfiles/Anthrax-8-pager1FINAL/$file/Anthrax-8-pager1FINAL.pdf

57. Additional options for preventive treatment for persons exposed to inhalational anthrax. MMWR Morb Mortal Wkly Rep 50:1142, 2001

58. Carucci JA, McGovern TW, Norton SA, et al: Cutaneous anthrax management algorithm. J Am Acad Dermatol (online), November 21, 2001

http://www.aad.org/BioInfo/Biomessage2.html

59. Biosafety in Microbiological and Biomedical Laboratories (BMBL) 4th Edition. U.S. Department of Health and Human Services Centers for Disease Control and Prevention and National Institutes of Health, May 1999. US Government Printing Office, Washington, DC, 1999

http://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm

60. Perry RD, Fetherston JD: Yersinia pestis--etiologic agent of plague. Clin Microbiol Rev 10:35, 1997 [PMID 8993858]

61. Gage KL, Dennis DT, Orloski KA, et al: Cases of cat-associated human plague in the western U.S., 1977-1998. Clin Infect Dis 30:893, 2000

62. Inglesby TV, Dennis DT, Henderson DA, et al: Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 283:2281, 2000

63. Prevention of plague. Recommendations of the Advisory Committee on Immunization Practice. MMWR Morb Mortal Wkly Rep 45:1 1996

64. McGovern TW, Friedlander AM: Plague. Medical Aspects of Chemical and Biological Warfare. Textbook of Military Medicine Series. Part I, Warfare, Weaponry and the Casualty. Sidell FR, Takafuji ET, Franz DR, Eds. TMM Publications, Washington, DC, 1997

65. Shapiro RL, Hatheway C, Becher J, et al: Botulism surveillance and emergency response: a public health strategy for a global challenge. JAMA 278:433, 1997 [PMID 9244338]

66. Shapiro RL, Hatheway C, Swerdlow DL: Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med 129:221, 1998 [PMID 9696731]

67. Arnon SS, Schechter R, Inglesby TV, et al: Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059, 2001 [PMID 11209178]

68. Cherington M: Clinical spectrum of botulism. Muscle Nerve 21:701, 1998 [PMID 9585323]

69. Woodruff BA, Griffin PM, McCroskey LM, et al: Clinical and laboratory comparison of botulism toxin types A, B and E in the United States, 1975-1988. J Infect Dis 166:1281, 1992 [PMID 1431246]

70. Angulo FJ, Getz J, Taylor JP, et al: A large outbreak of botulism: the hazardous baked potato. J Infect Dis 178:172, 1998 [PMID 9652437]

71. Eitzen E: Medical management of biological casualties, 3rd ed. U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, 1998

72. Black RE, Gunn RA: Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 69:567, 1980 [PMID 7191633]

73. Tularemia--United States, 1999-2000. MMWR Morb Mortal Wkly Rep 51:181, 2002

74. Feldman KA, Enscore RE, Lathrop SL, et al: An outbreak of primary pneumonic tularemia on Martha's Vineyard. N Engl J Med 345:1601, 2001

[PMID 11757506]

75. Dennis DT, Inglesby TV, Henderson DA, et al: Tularemia as a biological weapon: medical and public health management. JAMA 285:2763, 2001 [PMID 11386933]

76. Choi E: Tularemia and Q fever. Med Clinics North Am 86:393, 2002

77. Evans ME, Gregory DW, Schaffner W, et al: Tularemia: a 30-year experience with 88 cases. Medicine (Baltimore) 64:251, 1985

78. Gill V, Cunha BA: Tularemia pneumonia. Semin Respir Infect 12:61, 1997 [PMID 9097380]

79. Evans ME, Friedlander AM: Tularemia. Medical Aspects of Chemical and Biological Warfare. Textbook of Military Medicine Series. Part I, Warfare, Weaponry and the Casualty. Sidell FR, Takafuji ET, Franz DR, Eds. TMM Publications, Washington, DC, 1997

80. Limaye AP, Hooper CJ: Treatment of tularemia with fluoroquinolones: two cases and review. Clin Infect Dis 29:922, 1999 [PMID 10589911]

81. Borio L, Inglesby T, Peters CJ, et al: Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 287:2391, 2002 [PMID 11988060]

82. Khan AS, Sanchez A, Pflieger AK: Filoviral hemorrhagic fevers. Br Med Bull 54:675, 1998 [PMID 10326293]

83. Bwaka MA, Bonnet MJ, Calain P, et al: Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis 179:S1, 1999 [PMID 9988155]

84. Jahrling PB: Viral hemorrhagic fevers. Textbook of Military Medicine Series. Part I, Warfare, Weaponry and the Casualty. Sidell FR, Takafuji ET, Franz DR, Eds. TMM Publications, Washington, DC, 1997

85. Isaacson M: Viral hemorrhagic fever hazards for travelers in Africa. Clin Infect Dis 33:1707, 2001 [PMID 11595975]

86. Acute hemorrhagic fever syndrome. World Health Organization.

http://www.who.int/emcdocuments/surveillance/docs/whocdscsrisr992.html/41Acute%20haemorrhagic%20fever%20syndrome.htm

87. Update: management of patients with suspected viral hemorrhagic fever--United States. MMWR Morb Mortal Wkly Rep 44:475, 1995

© 2003 WebMD Inc. All rights reserved.